Background
==========

Mother-to-child HIV-1 transmission is the primary mode of pediatric infection. Over 50% of HIV-1 infected individuals around the world are women in their childbearing years \[[@B1],[@B2]\]. In the absence of intervention, more than a third of the children born to infected mothers acquire HIV-1 through mother-to-child transmission (MTCT) \[[@B3]-[@B5]\]. This accounts for up to 14% of all HIV-1 transmission \[[@B1],[@B5]\], with 370,000 infants infected in 2009. MTCT can occur during gestation, at delivery and through breastfeeding. Seventy-five percent of HIV-1 infected children die by the age of 3 years, accounting for up to 20% of all HIV-1 related deaths \[[@B6],[@B7]\]; in resource-limited settings, HIV-1 accounts for one third of all deaths among children under five \[[@B1]\].

Studies in multiple cohorts, across several clades, have demonstrated that a marked restriction in the diversity of founder viruses in blood and plasma is a hallmark of mucosal HIV-1 infection, including sexual transmission \[[@B8]-[@B12]\] and MTCT \[[@B13]\]. This restricted diversity suggests either the transmission or post-transmission amplification of a single donor variant in the majority of recipients \[[@B3],[@B14]-[@B16]\]. The genetic and biologic determinants of the transmission bottleneck are largely unknown.

The *env*glycoprotein (gp160*)*engages the HIV-1 receptor and co-receptors, mediating virus entry into cells \[[@B17]\], and is the primary target for neutralizing antibodies. *Env*is also the most variable HIV-1 gene. We therefore set out to extensively characterize the genotypes and phenotypes of full-length *env*molecular clones from HIV-1 infected mother-infant pairs. Better understanding of the genotypic and functional properties of transmitted *env*variants may facilitate the development of improved strategies to prevent MTCT.

Results
=======

Phylogeny of envelope sequences
-------------------------------

Full-length *env*genes were amplified from mother and infant patient plasma HIV-1 RNA (Table [1](#T1){ref-type="table"}). At least 10 clones were generated for each subject; 88% of *env*clones proved functional, with no significant differences in functionality between mothers and infants detected within or across transmission pairs (data not shown). A total of 162 functional maternal and infant *env*clones, each from an independent limiting dilution RT-PCR, were obtained and sequenced through the V1-V5 regions of the envelopes. A neighbor-joining tree was constructed by alignment of these nucleotide sequences (Figure [1A](#F1){ref-type="fig"}). For one patient (P1031), three clones were sequenced through V1-V3 only and are not included in the tree. The resulting tree revealed clear epidemiological linkage within each mother-infant pair, with no evidence of cross-pair or other contamination. Maximum likelihood trees and Highlighter alignments of non-gap stripped sequences were used to confirm phylogeny and select representative clones (data not shown).

###### 

Clinical and laboratory status of study participants

  Subject*^a^*   Birth year   Sample timing   Plasma viral load (copies/ml)   CD4    CD8    CD4:CD8   No. of *env*clones   No. of pseudo viruses   ART status
  -------------- ------------ --------------- ------------------------------- ------ ------ --------- -------------------- ----------------------- ------------
  M1003                       0               14158                           466    932    0.50      12                   4                       None
  P1189          1994         31              311538                          2872   1975   1.45      10                   2                       None
  M1002                       28              ND                              872    1225   0.71      25                   5                       None
  P1031          1992         54              685169                          2147   927    2.32      11                   3                       None
  M1001                       2               26000                           534    726    0.74      19                   4                       None
  P1024          1990         51              750000                          3312   4504   0.74      11                   2                       None
  M1007                       -8              ND                              870    1176   0.74      22                   4                       ZDV
  P1046          1995         66              1229730                         2573   1693   1.52      22                   4                       ZDV\*
  M1006                       -33             260541                          134    403    0.33      20                   5                       ZDV
  P1049          1999         30              647919                          ND     ND     ND        10                   2                       ZDV\*

*^a^*M, Mother; P, Infant. ZDV, Zidovudine administered to mother or infant to prevent MTCT. ND, Not determined. Timing of samples used for cloning in days after delivery; negative numbers indicate days before delivery.

![**Evolutionary relationships of HIV-1 *env*clones**. Evolutionary history was inferred using the Neighbor-Joining method. **(A)**V1-V5 nucleotide sequences of cloned *env*and subtype reference sequences. Filled triangle = infant, empty circle = maternal sequence. **(B)**Full length gp160 nucleotide sequences. M = maternal, P = infant. The percentage of replicate trees in which the associated sequences clustered together \>70% of the time in the bootstrap test (1000 replicates) are shown to the left of branches in **(B)**. The evolutionary distances were computed using the Kimura 2-parameter method. All positions containing gaps and missing data were eliminated from the dataset. Horizontal scale bars represent **(A)**5%, or **(B)**1% genetic distance.](1742-4690-8-67-1){#F1}

At least 2 clones were selected from each infant: the closest to and farthest from the consensus of the subject. In two cases where the infants were clearly infected with two maternal variants (P1031 and P1024; Figure [1A](#F1){ref-type="fig"}), clones from the major infant variant were selected as above, and the clone closest to the consensus of the minor infant variant was also included. At least four maternal clones were selected from each subject to sample the breadth of their quasispecies. Using Maximum Likelihood Trees, a maternal clone was selected from each of the two branches closest to the infant, and two additional clones were chosen from distantly related branches (data not shown). Full-length gp160 sequences of both DNA strands were obtained for the selected clones.

Full-length *env*sequences were obtained for all selected clones (Figure [1B](#F1){ref-type="fig"}), and the consensus gp160 sequence was determined for each infant. Of the 13 infant clones selected, four were identical to their infant\'s gp160 consensus. Eight clones differed from the consensus by two amino acids or less, one differed by three, and one (P1024 H2) differed by six. For two randomly selected infants (P1189 and P1049), consensus gp160 sequences generated by SGA were identical to those obtained by endpoint dilution PCR (data not shown). Phylogenetic analyses confirmed that all subjects were infected with subtype B.

Visual inspection of phylogenetic trees (Figure [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}) and Highlighter alignments (data not shown) of each mother-infant pair demonstrated probable transmission of a single maternal variant to infants P1189, P1049, and P1046, two variants to infant P1031 and two or three to infant P1024. Of the variants transmitted to P1024, two arose from very closely related viruses, or through post-transmission diversification (Figure [2](#F2){ref-type="fig"}). The relationship between maternal and infant quasispecies was further analyzed based on the paradigm described by Haaland *et al*. \[[@B18]\]. The number of amino acids differing between each infant variant and the most closely related maternal sequence in the V1-V5 region were determined, as were the number of maternal sequences differing from an infant variant by less than three amino acids (Table [2](#T2){ref-type="table"}). A maternal sequence differing from an infant variant by less than three amino acids likely gave rise to that variant. If such sequences represent less than 5% of the maternal quasispecies, a minor maternal variant was likely transmitted to the infant \[[@B18]\]. Infant P1024 was apparently infected with two or three minor variants of the maternal quasispecies, infant P1049 with a single major variant, infant P1031 with two minor variants, while infants P1189 and P1046 each received a single minor variant (Table [2](#T2){ref-type="table"}). Infant sequences were more homogeneous than maternal, with the mean diversity, measured by number of base substitutions per site within each subject ranging from 0.1 to 0.3% among infants, and 0.6 to 4.6% among mothers (Figure [3](#F3){ref-type="fig"}).

![**Highlighter analysis of infant P1024 V1-V5 sequences**. The subject quasispecies consists of three variants. Sequences belonging to the same variant are indicated by colored arrows. Pink and blue variants arose from transmission of two very closely related maternal viruses, or by post-transmission diversification. The brown variant arose from transmission of a distinct maternal virus.](1742-4690-8-67-2){#F2}

###### 

Relationship of maternal and infant V1-V5 sequences

  Infant   Sequences analyzed*^a^*   Differences*^b^*   Less than 3 differences*^c^*
  -------- ------------------------- ------------------ ------------------------------
  P1189    12                        1                  1
  P1031    25                        3                  0
                                     11                 0
  P1024    19                        5                  0
                                     3                  0
                                     3                  0
  P1046    22                        1                  1
  P1049    20                        2                  4

*^a^*Number of maternal sequences analyzed.

*^b^*Number of amino acids that differ between an infant variant consensus sequence and the most closely related maternal sequence.

*^c^*Number of maternal sequences differing from the infant variant consensus by less than 3 amino acids.

![**Infant quasispecies are more homogeneous than maternal**. The percent of base substitutions per site over the V1-V5 region for each subject were computed using the Kimura 2-parameter method in the MEGA4 software program.](1742-4690-8-67-3){#F3}

The consensus sequence of clones amplified shortly following transmission from a subject infected with a single donor variant represents the sequence of the transmitted/founder virus \[[@B18]\]. We compared maternal gp160 sequences to the consensus of each infant variant to determine how closely clones selected for their similarity to infant *env*approached the transmitted/founder sequence. Maternal clones most closely related to their infants were; M1003 P16 which differed from the infant consensus by three amino acid substitutions, M1001 J7 which differed by four amino acids substitutions, M1007 T1 which differed by three amino acids, M1006 X1 which differed by three substitutions, and M1002 J4 which differed by 15 amino acids. No maternal sequence was identical to the consensus of an infant variant. We then compared the maternal sequences to each individual sequence amplified from her infant and did not detect any maternal sequence identical to any infant sequence.

*Env*V1-V5 length, glycosylation and co-receptor tropism
--------------------------------------------------------

Since *env*length and glycosylation have been reported to correlate with mucosal transmission, including MTCT \[[@B15]\], we investigated these factors in our panel. In pairs M1001-P1024 and M1007-P1046, the median V1-V5 length of infant sequences was greater than maternal, while in pairs M1002-P1031, M1006-P1049, and M1003-P1189, the medians were similar (Table [3](#T3){ref-type="table"}). The median number of V1-V5 PNGS was smaller in the infant sequences than in the mother\'s for pair M1002-P1031, greater for pair M1001-P1024, and equal in pairs M1007-P1046, M1006-P1049 and M1003-P1189 (Table [3](#T3){ref-type="table"}). Statistical analysis did not indicate significant within-pair differences in the mean *env*length or glycosylation between maternal and infant clones. The V3 loop charge and glycosylation are predictive of co-receptor tropism \[[@B19],[@B20]\]. Examination of charge and glycosylation of the V3 loops of our *env*clones did not reveal any CXCR4 (X4) tropic variants in our panel and only one mother (M1006), was predicted to harbor CCR5/CXCR4 dual tropic variants. Only CCR5 (R5) tropic maternal variants were transmitted to the infants (Table [3](#T3){ref-type="table"}).

###### 

Genotypic analyses of V1-V5 sequences

  Subject*^a^*   **V1-V5 length*^b^***\*   **V1-V5 PNGS*^c^***\*   V3 charge   V3 glycan   V3 crown motif*^d^*   Tropism*^e^*
  -------------- ------------------------- ----------------------- ----------- ----------- --------------------- --------------
  M1003          335                       24 (23-25)              +3          Yes         APGR                  R5
  P1189          335                       25 (25-25)              +3          Yes         APGR                  R5
  M1002          329 (329-333)             21 (20-24)              +3          Yes         GPGR                  R5
  P1031          329 (329-330)             19 (19-20)              +3          Yes         GPGR                  R5
  M1001          345 (342-347)             23 (22-25)              +2          Yes         GPGG, GPGR            R5
  P1024          346 (345-346)             24 (23-24)              +2          Yes         GPGR                  R5
  M1007          328 (328-335)             23 (22-24)              +4          Yes         GPGR                  R5
  P1046          335                       23 (21-23)              +4          Yes         GPGR                  R5
  M1006          332 (320-349)             24 (17-26)              +3 +4 +5    Yes, No     QPGR, QPGG            R5, R5/X4
  P1049          332                       24 (24-24)              +3          Yes         QPGR                  R5

*^a^*M, Mother; P, Infant.

*^b^*Median length of the *env*V1-V5 region as median (min-max).

*^c^*Median number of potential N-linked glycosylation sites in the V1-V5 region as median (min-max).

*^d^*Dominant variant presented first.

*^e^*Tropism determined *in-vitro*. R5, CCR5; R5/X4, CCR5/CXCR4.

\*p \> 0.05. Pairwise differences between maternal and infant values were evaluated using Mixed Model ANOVA with mother-infant pairs included as random effects.

Receptor and co-receptor requirements
-------------------------------------

The *in-silico*R5 tropism predictions were confirmed *in vitro*by comparing titers on the TZMbl and HIJ cell lines. TZMbl express both the CCR5 and CXCR4 co-receptors, while HIJ express CXCR4 but not CCR5 \[[@B21]\]. Pseudoviruses expressing the X4 tropic NL4.3 *env*and the R5 tropic SF162 *env*were used as controls; NL4.3 *env*infected both cell lines while SF162 *env*infected only TZMbl. All maternal and infant clones achieved high titers on TZMbl, but only one maternal clone (M1006 P1) infected both cell lines (Figure [4A](#F4){ref-type="fig"}).

![**Receptor and co-receptor requirements of cloned *env***. Pseudoviruses expressing cloned *env*were titered on HeLa cell lines engineered to express various levels of CD4 and CCR5. To normalize between different pseudovirus preparations, titers are expressed as a ratio of the titer on the cell line divided by the titer on TZMbl cells. **(A)**TZMbl, **(B)**JC37, **(C)**JC10, **(D)**RC49, **(E)**RC23. Results are an average of 3 independent experiments performed in duplicate. Average number of receptor and co-receptor molecules per cell as reported by Platt et al \[[@B21]\] is inset in the charts. Filled triangle = infant, empty circle = maternal. Pairwise statistical analysis performed using the Mixed Model ANOVA with mother-infant pairings included as random effects indicated that mean maternal and infant titers did not vary significantly across pairs.](1742-4690-8-67-4){#F4}

The receptor (CD4) and co-receptor (CCR5) use of representative maternal and infant *env*clones (*n*= 35, Figure [1B](#F1){ref-type="fig"}) was then analyzed in depth. Pseudoviruses expressing these *env*were generated and titered on TZMbl cells (Figure [4A](#F4){ref-type="fig"}), and on additional HeLa cell lines expressing varying levels of CD4 and CCR5 \[[@B21]\] (Figure [4B-E](#F4){ref-type="fig"}). Infant viruses infected all cell lines tested. When pairwise comparisons were made, there was no significant difference between the mean infant and maternal titers on any cell line. All clones achieved highest titers on TZMbl cells, which express the highest levels of CD4 and CCR5. Titers decreased with decreasing levels of CD4 (Figure [4B](#F4){ref-type="fig"} verses D) or CCR5 (Figure [4B](#F4){ref-type="fig"} verses C, and D verses E), but were more sensitive to changes in CD4.

Replication in primary macrophages and PBL
------------------------------------------

We used two different approaches to evaluate the ability of maternal and infant viruses to replicate in primary macrophages. First, we investigated the ability of pseudoviruses expressing the *env*clones to mediate infection of primary macrophage cultures in a single round infection. All infant viruses exhibited low or no infectivity in monocyte derived macrophages (MDM); similarly, only a single maternal clone (M1002 G1) attained a high level of infection as compared to the non-macrophage tropic and highly macrophage tropic controls (Figure [5](#F5){ref-type="fig"}). Macrophage infectivity was further investigated by infecting matched donor MDM and PBLs with EGFP-tagged recombinant *env*clones from two randomly selected mother-infant pairs (Table [4](#T4){ref-type="table"}). No fluorescence was detected in macrophage cultures throughout two weeks of infection while high levels of fluorescence were detected in each PBL infection. Measurement of HIV-1 p24 in the supernatants collected from cultures over the course of infection showed a steady decline from the input levels of p24 in macrophage infections, while PBL infections showed an increase. Altogether, these data demonstrate robust replication in PBL but uniformly poor replication in macrophages.

![**Macrophage infectivity**. Pseudoviruses expressing cloned envelopes were titered on primary macrophage cultures. Macrophage infectivity is expressed as the percentage of the TZMbl titer achieved on macrophages. Data is representative of three independent assays performed in duplicate. Filled triangle = infant, empty circle = maternal. Clone M1002 G1 is highlighted red. Cont = Controls \[[@B42]\], see inset key: (macrophage tropic) NA20 B59, NA420 B33 and JRFL, (non-macrophage topic) JRCSF, NA420 LN40 and NA20 LN8.](1742-4690-8-67-5){#F5}

###### 

Maternal and infant viruses replicate well in PBL but poorly in MDM

                 Fluorescence   p24 ELISA*^a^*             
  -------------- -------------- ---------------- --------- ---------
  **Clone ID**   **MDM**        **PBL**          **MDM**   **PBL**
                                                           
  M1003 P16      No             Yes              No        Yes
  M1003 D6       No             Yes              No        Yes
  M1003 O1       No             Yes              No        Yes
  M1003 Q4       No             Yes              No        Yes
  P1189 F3       No             Yes              No        No
  M-1007 Z8      No             Yes              No        Yes
  M-1007 Q8      No             Yes              No        Yes
  M-1007 Y7      No             Yes              No        Yes
  P-1046 W2      No             Yes              No        Yes
  P-1046 C4      No             Yes              No        Yes
  P-1046 J1      No             Yes              No        Yes
  P-1046 K1      No             Yes              No        Yes

*^a^*Increase in p24 antigen levels above input.

Infections with clones from the M1003-P1189 transmission pair were carried out at an MOI of 0.01, while those from the transmission pair M1007-P1046 were done at an MOI of 0.001.

Sensitivity of envelope clones to neutralization by autologous maternal plasma
------------------------------------------------------------------------------

We assayed at least three clones from each mother-infant pair. Relatively high levels (≥ 100 μg/ml) of autologous maternal plasma IgG were required to neutralize maternal and infant viruses (Figure [6A](#F6){ref-type="fig"}). Statistical analysis did not indicate significant within-pair differences in the susceptibility of maternal and infant clones to neutralization by autologous maternal IgG.

![**Sensitivity of maternal and infant *env*to neutralization or inhibition**. The sensitivity of infant and maternal clones to **(A)**autologous maternal IgG, **(B)**NAbs, **(C)**pooled seropositive plasma and **(D)**entry inhibitors was determined using pseudovirus infection of TZMbl cells. **(A)**Neutralization IC~50~of maternal and infant *env*clones. Lines indicate maximum concentration of IgG. **(B-D)**Values are an average of two different pseudovirus stocks run in the same experiment. Solid lines indicate infant and maternal means. Dotted lines in **(B)**indicate maximum concentration of NAb used. Filled triangle = infant, empty circle = maternal. Pairwise statistical analysis performed using the Mixed Model ANOVA with mother-infant pairings included as random effects indicated that mean maternal and infant IC~50~did not vary significantly across pairs.](1742-4690-8-67-6){#F6}

Sensitivity of envelope clones to neutralization by monoclonal antibodies and pooled seropositive plasma
--------------------------------------------------------------------------------------------------------

Using a standardized assay \[[@B22],[@B23]\], we tested the neutralization sensitivity profile of our pseudoviruses to a panel of well-established human NAbs, including b12 (CD4 binding site), 2G12 (carbohydrate-dependent) and the gp41 Membrane Proximal External Repeat (MPER) specific NAbs 2F5 and 4E10 (Figure [6B](#F6){ref-type="fig"}). No infant or maternal clone was resistant to 2F5. Only one clone was resistant to 4E10 (P1046 J1) and expressed the rare, resistance conferring, natural polymorphism F673L \[[@B24],[@B25]\]. All clones from three infants were resistant to 20 μg of 2G12 and exhibited mutations eliminating one of five PNGS implicated in 2G12 binding \[[@B26]\]. In infant P1024, the mutation was N386D, in P1049 it was N392K, and in P1046 it was T292I. Most maternal clones from these pairs exhibited similar levels of 2G12 resistance, and displayed the corresponding mutations. Infants P1031, P1046 and P1049 had some clones resistant to 20 μg of b12, but each had one sensitive clone. A similar pattern of sensitive and resistant clones was seen in the corresponding mothers. When pairwise analyses were performed, we did not detect any trends for differential neutralization sensitivity between infant and maternal variants.

The neutralization sensitivity of the pseudoviruses to pooled heterologous plasma with high NAb activity was next determined (Figure [6C](#F6){ref-type="fig"}). Sensitivity varied over a 4-fold range within mother-infant pairs, but all infant and maternal viruses were sensitive to neutralization at plasma reciprocal dilutions ranging from 109 to 1588. Pairwise analysis failed to detect any trends for within-pairs differences in neutralization sensitivity to this reagent.

Sensitivity of infant envelope clones to HIV-1 entry inhibitors
---------------------------------------------------------------

The sensitivity of infant clones to three HIV-1 entry inhibitors was evaluated (Figure [6](#F6){ref-type="fig"} and data not shown). The inhibitors used were sCD4, T20 (fusion inhibitor) and Maraviroc (CCR5 antagonist). Since Maraviroc is a non-competitive inhibitor, we determined the MPI of our clones by this inhibitor. All clones were inhibited by \>99% at concentrations exceeding 400 nM, indicating that none were resistant \[[@B27],[@B28]\]. The NL4.3 *env*control exhibited a MPI of \<2% (data not shown).

Infant clones were sensitive to T20 and sCD4, exhibiting IC~50~ranges similar to the maternal. Mean T20 IC~50~for infant clones was 0.23 μg/ml and 0.24 μg/ml for maternal. Soluble CD4 exhibited a mean IC~50~of 7.24 μg/ml for infants and 6.43 μg/ml for mothers. No significant within-pair differences in sensitivity to these inhibitors were observed between maternal and infant viruses.

Discussion
==========

We generated full-length viable *env*clones from 5 mother-infant pairs and extensively characterized their V1-V5 genotypes and phylogeny. Phylogenetic analyses showed that infant sequences were more homogeneous than maternal viral sequences. The highest sequence diversity seen in the infants, 0.3%, fits well with the model of Keele *et al*. \[[@B9]\], which indicates that the maximum diversity expected within an individual shortly after infection with a single virus is 0.6%. Of the 8 transmitted/founder variants identified in the infants of our cohort, seven represented minor variants of the maternal quasispecies at the time of sampling, which was within a few weeks of transmission. These data support previous findings \[[@B13],[@B14],[@B29]\] suggesting a selective bottleneck during MTCT.

Consensus gp160 endpoint dilution sequences from two randomly selected infants were identical to those obtained by SGA. These results are compatible with a recent report that standard PCR and SGA provide similar measures of viral diversity when sufficient templates are analyzed \[[@B30]\].

Several groups have reported shorter hypervariable regions and fewer N-linked glycosylation sites in Clade C sexually (reviewed \[[@B31]\]) or maternally \[[@B32]\] transmitted viruses. Our data on Clade B viruses are compatible with others\' work that did not find altered *env*length or glycosylation site number in transmitted Clade B viruses \[[@B33]\].

All infant clones were R5 tropic, consistent with numerous prior reports \[[@B34]-[@B36]\]. *Intrapartum*transmission of HIV-1 is hypothesized to occur across the mucosa, although the exact mechanisms have not been determined (reviewed \[[@B37],[@B38]\]). Efficient HIV-1 infection usually requires the expression of relatively high levels of the CD4 receptor and CCR5 co-receptor on the surface of target cells \[[@B21],[@B39]\]. However, levels of CD4 and CCR5 on mucosal and submucosal cell subsets can be much lower than on CD4^+^memory T cells \[[@B40]\]. Titration on cell lines expressing different levels of CD4 and CCR5 demonstrated efficient infection of cells with variable levels of these molecules. This finding is supported by our failure to observe any systematic differences in the sensitivity of maternal and infant *env*to inhibition by sCD4 or CCR5 inhibitors. It is also in agreement with a recent report that sexual HIV-1 transmission does not appear to select for viruses that can preferentially utilize lower levels of CD4 or CCR5 \[[@B39]\].

CCR5 co-receptor usage has traditionally been equated with macrophage-tropism. Peters *et al*. have recently clarified that not all R5 viruses are macrophage-tropic (reviewed \[[@B41]\]). Only 1 of 35 plasma-derived *env*clones achieved greater than 1% of their TZMbl titers on MDM. Our results are in agreement with prior data \[[@B42]\] demonstrating that peripheral blood viruses frequently exhibit low levels of macrophage infectivity, and that sexually transmitted R5 tropic variants replicate poorly in macrophages \[[@B43],[@B44]\]. Finally, these findings support recent models of HIV-1 transmission, which suggest that cell subtypes other than macrophages are the first to encounter HIV-1 during mucosal transmission \[[@B44],[@B45]\].

We screened our clones to determine their sensitivity to neutralization by a panel of well-characterized monoclonal Nabs. Sensitivity to these NAbs varied both between and within mother-infant pairs. Clones were uniformly sensitive to 2F5. Only one clone (from infant P1046) was resistant to 4E10; this clone exhibited the F673L natural polymorphism associated with resistance to this Nab \[[@B24]\]. All clones with 2G12 resistance correlated with loss of one of five PNGS that make up the 2G12 epitope.

At least two groups have reported that infant *env*clones are relatively resistant to neutralization by autologous maternal plasma \[[@B15],[@B46]\]. Relatively high levels (IC~50~≥ 100 μg/ml) of autologous maternal plasma IgG were required to neutralize maternal and infant viruses; however, all infant viruses were neutralized by pooled sera from HIV-1 infected individuals, implying that they were not inherently neutralization-resistant.

CCR5 antagonists are a potent new class of entry inhibitors. Since only R5 variants are vertically transmitted, CCR5 antagonists may be highly relevant to blocking MTCT; however their effectiveness against infant isolates has not been well characterized, and partial resistance to CCR5 antagonists in a treatment-naïve individual has been reported \[[@B28]\]. All *env*clones in our panel were sensitive to Maraviroc. All infant clones were also sensitive to T20 and sCD4, and no significant differences in sensitivity were seen between maternal and infant viruses. The latter is in contrast with data from Keele *et al*. \[[@B9]\], who demonstrated significantly higher IC~50~values for T1249, a fusion inhibitor with a mechanism of action similar to T20, among viruses from acutely infected as compared to chronically infected subjects.

Conclusions
===========

Although we have a relatively small sized patient cohort, the results of our extensive genotypic and phenotypic studies confirm that clade B MTCT occurs across a selective bottleneck, and that neither *env*length nor glycosylation appear to play a role in this selection. Utilization of low receptor and co-receptor levels for entry likewise does not appear to play a major role in the selective bottleneck during vertical transmission of HIV-1 clade B. Most intriguingly, R5 tropic maternal and infant *env*exhibited poor macrophage infectivity. Relatively high levels (IC~50~≥ 100 μg/ml) of autologous maternal plasma IgG were required to neutralize maternal and infant viruses. Maternal and infant clones were equally sensitive to pooled heterologous plasma, implying that inherent neutralization resistance is unlikely to be a major factor controlling the selective bottleneck. Infant clones were variably sensitive to neutralization by monoclonal antibodies but uniformly sensitive to HIV-1 entry inhibitors. Together, our findings provide further insight into the selective pressures influencing the genetic bottleneck during vertical transmission of HIV-1 and may help inform the future development of therapies to prevent MTCT.

Materials and methods
=====================

Study population
----------------

Plasma samples were obtained from 5 HIV-1 clade B infected women and their infants (Table [1](#T1){ref-type="table"}). Maternal samples were obtained at or within a month of delivery. None of the mothers exhibited opportunistic infections or AIDS-defining illnesses. All five infants were infected at delivery, based on standard definitions \[[@B5]\]. Most *intrapartum*transmission is thought to occur across the mucosa although the exact mechanisms have not been determined (reviewed \[[@B37],[@B38]\]). None of the infants were breastfed. Infant samples were obtained within 2 months of delivery and represent the first time point at which HIV-1 was detected in the infants by viral isolation or the detection of nucleic acids.

PCR amplification and generation of functional envelope (gp160) clones via endpoint dilution
--------------------------------------------------------------------------------------------

Viral RNA was extracted from 50-200 μl of plasma using the Roche High Pure Viral RNA Kit (Roche Pharmaceuticals, Basel, Switzerland). Eluted RNA was treated with 1 μl of RNasin Plus RNase inhibitor (Promega Biosciences, San Luis Obispo, CA), then aliquoted and stored at -80°C. Full-length HIV-1 gp160 was amplified directly from the viral RNA by endpoint dilution nested RT-PCR. To identify the endpoint dilutions, RT-PCR was performed in octuplet on two fold serial dilutions of each viral RNA extract until a dilution was reached where not more than three of eight wells showed product. Outer and inner primer pairs were the same as reported by Wei *et al*. \[[@B47]\]. RT-PCR was performed using the Superscript One Step RT-PCR for Long Templates kit (Invitrogen Life Technologies, Carlsbad, CA). Conditions for the outer PCR were as follows: 45°C for 30 min, 94°C for 2 min, 40 cycles of 94°C for 15 sec, 52°C for 30 sec, 68°C for 3 min, with a final extension at 72°C for 10 min. Inner PCR was performed using the Platinum Taq DNA Polymerase HighFidelity kit (Invitrogen Life Technologies, Carlsbad, CA). Conditions for the inner PCR were as follows: 94°C for 2 min, 40 cycles of 94°C for 15 sec, 55°C for 30 sec, 68°C for 3 min, with a final extension at 72°C for 10 min. The \~3 kb *env*amplicons were sub-cloned into the pcDNA3.1/V5-His TOPO TA vector (Invitrogen Life Technologies, Carlsbad, CA) using the manufacturer\'s instructions. Colonies containing full length inserts in the correct orientation were identified by a PCR screen; their functionality was determined using syncytia as a readout by the addition of HeLa cells expressing CD4 and CCR5 (TZMbl a.k.a. JC53BL \[[@B21],[@B48]\]) to monolayers of 293T cells \[[@B49]\] transfected with the molecularly cloned *env*\[[@B50]\]. At least 10 functional *env*clones were obtained from each subject, with each clone originating from an independent endpoint dilution PCR.

Single genome amplification (SGA)
---------------------------------

SGA was performed as described by Salazar-Gonzalez *et al*. \[[@B10]\]. Briefly, viral RNA extracted as above was reverse transcribed to single-stranded cDNA using primer OFM1. The cDNA was diluted in 96 well plates such that less than 30% of the reactions yielded amplified product. Nested PCR was then carried out using primers Vif1 and OFM19 for the outer step, and EnvA and EnvN for the inner. All correctly sized products were purified and sequenced.

DNA sequencing, phylogenetic analysis and clone selection
---------------------------------------------------------

The V1-V5 regions of all viable molecular *env*clones were sequenced using BigDye Terminator chemistry. Sequences were assembled using the Vector NTI software (Invitrogen Life Technologies, Carlsbad, CA). *Env*sequences from each subject were aligned using ClustalW in the software package BioEdit <http://www.mbio.ncsu.edu/BioEdit/BioEdit.html>, and trees were constructed using the neighbor joining method \[[@B51]\] implemented in Mega <http://www.megasoftware.net> using Kimura\'s correction \[[@B52]\] and 1000 iterations of Bootstrap analysis, and the maximum likelihood method with 500 iterations of Bootstrap analysis implemented in PhyML <http://www.hiv.lanl.gov>. Phylogeny was confirmed using the Highlighter software program <http://www.hiv.lanl.gov>. Potential N-Linked glycosylation sites (PNGS) were identified using the N-Glycosite program <http://www.hiv.lanl.gov>. The V3 loop charge was determined by comparing the number of positively charged (Aspartic Acid and Glutamic Acid) to negatively charged (Lysine and Arginine) amino acid residues.

Pseudovirus production and titration
------------------------------------

Pseudoviruses were made by co-transfecting exponentially dividing 293T cells with a 1:2 ratio of *env*and pSG3Δ*env*backbone (NIH AIDS Research and Reference Reagent Program \[[@B47],[@B53]\]) using Polyethylenimine (Polysciences, Warrington, PA) as the transfection reagent. Pseudoviral titers were determined using single round infection of TZMbl cells essentially as described \[[@B23]\] except that β-galactosidase staining rather than luminescence was used as the readout. Cells developed using the β-galactosidase readout were counted on an automated ELISPOT reader (See Additional File [1](#S1){ref-type="supplementary-material"}; Supplemental Methods). The titers were expressed as spot forming units per ml (sfu/ml). Assays utilizing luminescence gave results very similar to those determined by using β-galactosidase (data not shown). Titrations were performed at least twice for each pseudovirus.

Construction of replication competent fluorescently tagged HIV-1
----------------------------------------------------------------

A fluorescently tagged, replication competent HIV-1 backbone was obtained from Dr. Matthias Dittmar (Centre for Infectious Disease, Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry). Plasmids encoding selected infant and maternal *env*in this backbone were generated as described \[[@B54]\]. Briefly, we used the plasmid TN6GΔ, which encodes the full length NL4.3 HIV-1 clone with the *nef*gene replaced by EGFP and has unique restriction sites (*Bst*EII and *Nco*I) in the *env*gene available for inserting heterologous *env*. The complementary restriction sites were introduced into selected infant and maternal *env*clones and used for directional sub-cloning into TN6GΔ. Live, fluorescently tagged virus was produced using essentially the same protocol as for the pseudovirus described above.

Cell line, macrophage, and peripheral blood lymphocyte (PBL) titrations and infections
--------------------------------------------------------------------------------------

Receptor and co-receptor requirements of pseudoviruses were determined by titration on HeLa cells engineered to express various levels of the CD4 receptor and CCR5 and CXCR4 co-receptors \[[@B21]\]. *In silico*predicted CCR5 tropism was confirmed by titration on the HIJ HeLa cell line, which expresses CD4 and CXCR4 but no CCR5 \[[@B21]\], using pseudoviruses expressing the CXCR4 tropic NL4.3 *env*\[[@B55]\] and the CCR5 tropic SF162 *env*(NIH AIDS Research and Reference Reagent Program Catalog \# 10463) as controls. Titrations were performed as described \[[@B50]\] utilizing anti-p24 immunostaining as the infectivity readout. To determine macrophage infectivity, elutriated monocytes were re-suspended in medium containing macrophage colony stimulating factor and cultured for seven days before use for pseudoviral titrations essentially as described \[[@B50]\]. Each pseudovirus was tested in duplicate in 3 independent assays. To normalize between different pseudoviral preparations, all titers are expressed as a ratio of the titer on the cell line or macrophage culture divided by the titer on TZMbl cells.

For infection of PBLs, fresh PBLs were maintained in RPMI 1640 medium supplemented with 10% FBS, stimulated with phytohemagglutinin (5 μg/ml) for 2 days, and interleukin-2 (10 U/ml) for a further 2 days prior to infection. PBLs were infected with live virus at an MOI of 0.01 or 0.001 as indicated (based on TZMbl or PBL titers as appropriate) and carried for seven days before being read for HIV-1 positive cells by anti-p24 immunostaining or flow cytometry.

Neutralization and inhibition assays
------------------------------------

Neutralization and inhibition assays using human monoclonal antibodies, pooled HIV-positive patient sera, autologous maternal plasma, or HIV-1 entry inhibitors were performed as previously described \[[@B22],[@B23],[@B56]-[@B58]\], using 200 sfu of pseudovirus to infect TZMbl cells, with residual infection measured using the β-galactosidase readout. To determine the activity of CCR5 antagonists, the assay was modified such that cell monolayers were incubated with serial dilutions of the inhibitors for one hour before the addition of virus. Following the addition of virus, plates were incubated overnight and the media was replaced with fresh un-supplemented media. Pseudoviral stocks expressing well-characterized *env*from the NIH AIDS Research and Reference Reagent Program Standard Reference Panels of Subtype B or C HIV-1 *Env*Clones \[[@B22],[@B56],[@B57]\] were used in every experiment and showed low intra-assay variation, and values similar to those reported \[[@B56],[@B57]\] (data not shown). Monoclonal NAbs b12, 2G12, 4E5, and 2F5 were obtained from the NIH AIDS Research and Reference Reagent Program; an additional aliquot of b12 was generously provided by Dr. Dennis Burton (Scripps Research Institute). The maximum b12 and 2G12 antibody concentration used in neutralization assays was 20 μg/ml, while 4E10 and 2F5 were used at 50 μg/ml. HIV-1 entry inhibitors soluble CD4 (sCD4, Progenics Pharmaceuticals, Tarrytown, NY), Enfuvirtide (T20, Roche, Palo Alto, CA) and Maraviroc (obtained through the NIH AIDS Research and Reference Reagent Program) were also evaluated in these assays. As Maraviroc is a non-competitive inhibitor, resistance was determined by changes in the maximal percent inhibition (MPI) \[[@B59]\]. The MPI of our clones was determined by observing plateaus in the inhibition curves \[[@B59]\] at saturating concentrations of Maraviroc (up to 4000 nM) \[[@B28],[@B59]\]. All plasma was heat inactivated at 56°C for 30 minutes before use. Sero-negative plasma was used as a negative control and showed no neutralization activity at 1:15 dilution. Pseudovirus expressing murine leukemia virus (MLV) *env*was used as a non-specific neutralization control and generally failed to be inhibited by the highest concentration of plasma used. Since we have previously observed non-specific neutralization of the MLV control and available plasma volumes were limited, we used purified Immunoglobulin G (IgG) in our autologous neutralization assays (see below). For all antibodies and inhibitors, the 50% inhibitory concentration (IC~50~) relative to untreated control infections was determined from plots generated using the sigmoidal fit function of the OriginPro 7.5 SRO v7 software package \[[@B60]\] (See Additional File [1](#S1){ref-type="supplementary-material"}; Supplemental Methods).

Autologous neutralization using purified IgG
--------------------------------------------

IgG was purified from plasmas using the Nab Protein Spin Kit (Thermo Scientific, Rockford, IL) according to the manufacturer\'s protocol. Elution fractions one and two were pooled and dialyzed in culture media using the Slide-A-Lyzer Dialysis Kit, 10 K MWCO (Pierce Biotechnology, Rockford, IL). The amount of IgG in the dialyzed extracts and the original maternal plasma was quantified using the Human IgG ELISA Kit (ZeptoMetrix Corporation, Baffalo, NY). Autologous neutralizations were set up at an initial IgG concentration of 0.5 mg/ml.

Statistical analyses
--------------------

Pairwise differences between maternal and infant values were evaluated using Mixed Model ANOVA \[[@B61]\] with mother-infant pairs included as random effects. The analyses were performed using the Proc Mixed procedure \[[@B62]\] in the SAS statistical Software package (SAS Inc, NC, USA). Significance was reported when p ≤ 0.05.

Nucleotide sequence accession numbers
-------------------------------------

Nucleotide sequence accession numbers are available under \[GenBank: [HM368224](HM368224) - [HM368258](HM368258)\].
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